Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative drugs work by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these agents enhance insulin secretion and reduce glucagon secretion

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant traction. These medications offer promising approaches for controlling blood sugar levels and may improve the lives of individuals living with diabetes. Reta| acts by slowing